-
1
-
-
77649137632
-
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase i open-label multicenter trial in patients with advanced cancer
-
Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16: 1613-1623
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1613-1623
-
-
Banerji, U.1
Camidge, D.R.2
Verheul, H.M.3
Agarwal, R.4
Sarker, D.5
Kaye, S.B.6
Desar, I.M.7
Timmer-Bonte, J.N.8
Eckhardt, S.G.9
Lewis, K.D.10
Brown, K.H.11
Cantarini, M.V.12
Morris, C.13
George, S.M.14
Smith, P.D.15
Van Herpen, C.M.16
-
2
-
-
19644397029
-
Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
-
DOI 10.1038/sj.onc.1208544
-
Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24: 3459-3471 (Pubitemid 40756247)
-
(2005)
Oncogene
, vol.24
, Issue.21
, pp. 3459-3471
-
-
Bhatt, K.V.1
Spofford, L.S.2
Aram, G.3
McMullen, M.4
Pumiglia, K.5
Aplin, A.E.6
-
3
-
-
0037147122
-
Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation
-
DOI 10.1074/jbc.M208086200
-
Biswas SC, Greene LA (2002) Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem 277: 49511-49516 (Pubitemid 36014388)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.51
, pp. 49511-49516
-
-
Biswas, S.C.1
Greene, L.A.2
-
4
-
-
43749087380
-
V600E signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells
-
DOI 10.1038/sj.onc.1210972, PII 1210972
-
Cui Y, Guadagno TM (2008) B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene 27: 3122-3133 (Pubitemid 351693167)
-
(2008)
Oncogene
, vol.27
, Issue.22
, pp. 3122-3133
-
-
Cui, Y.1
Guadagno, T.M.2
-
5
-
-
55249124825
-
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells
-
Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112: 2439-2449
-
(2008)
Blood
, vol.112
, pp. 2439-2449
-
-
Dai, Y.1
Chen, S.2
Pei, X.Y.3
Almenara, J.A.4
Kramer, L.B.5
Venditti, C.A.6
Dent, P.7
Grant, S.8
-
6
-
-
34548097240
-
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
-
DOI 10.1158/1535-7163.MCT-07-0231
-
Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6: 2209-2219 (Pubitemid 47294749)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.8
, pp. 2209-2219
-
-
Davies, B.R.1
Logie, A.2
McKay, J.S.3
Martin, P.4
Steele, S.5
Jenkins, R.6
Cockerill, M.7
Cartlidge, S.8
Smith, P.D.9
-
7
-
-
0034652115
-
Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
-
DOI 10.1073/pnas.97.4.1578
-
Deng X, Ruvolo P, Carr B, May Jr WS (2000) Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97: 1578-1583 (Pubitemid 30118484)
-
(2000)
Proceedings of the National Academy of Sciences of the United States of America
, vol.97
, Issue.4
, pp. 1578-1583
-
-
Deng, X.1
Ruvolo, P.2
Carr, B.3
May Jr., W.S.4
-
8
-
-
3142683869
-
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
-
DOI 10.1038/sj.onc.1207692
-
Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23: 5301-5315 (Pubitemid 39005806)
-
(2004)
Oncogene
, vol.23
, Issue.31
, pp. 5301-5315
-
-
Domina, A.M.1
Vrana, J.A.2
Gregory, M.A.3
Hann, S.R.4
Craig, R.W.5
-
9
-
-
34250892541
-
L
-
DOI 10.1038/sj.emboj.7601723, PII 7601723
-
Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ (2007) ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 26: 2856-2867 (Pubitemid 46975775)
-
(2007)
EMBO Journal
, vol.26
, Issue.12
, pp. 2856-2867
-
-
Ewings, K.E.1
Hadfield-Moorhouse, K.2
Wiggins, C.M.3
Wickenden, J.A.4
Balmanno, K.5
Gilley, R.6
Degenhardt, K.7
White, E.8
Cook, S.J.9
-
11
-
-
33847066413
-
Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response
-
Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67: 1046-1053
-
(2007)
Cancer Res
, vol.67
, pp. 1046-1053
-
-
Golding, S.E.1
Rosenberg, E.2
Neill, S.3
Dent, P.4
Povirk, L.F.5
Valerie, K.6
-
12
-
-
40749124035
-
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
-
DOI 10.1158/1078-0432.CCR-07-1440
-
Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14: 230-239 (Pubitemid 351378000)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 230-239
-
-
Haass, N.K.1
Sproesser, K.2
Nguyen, T.K.3
Contractor, R.4
Medina, C.A.5
Nathanson, K.L.6
Herlyn, M.7
Smalley, K.S.M.8
-
13
-
-
0034644702
-
Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole
-
Hayne C, Tzivion G, Luo Z (2000) Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J Biol Chem275: 31876-31882
-
(2000)
J Biol Chem
, vol.275
, pp. 31876-31882
-
-
Hayne, C.1
Tzivion, G.2
Luo, Z.3
-
14
-
-
77954615408
-
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo
-
Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9: 1956-1967
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1956-1967
-
-
Hirai, H.1
Sootome, H.2
Nakatsuru, Y.3
Miyama, K.4
Taguchi, S.5
Tsujioka, K.6
Ueno, Y.7
Hatch, H.8
Majumder, P.K.9
Pan, B.S.10
Kotani, H.11
-
15
-
-
77958503710
-
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
-
Infante J, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA, Messersmith WA (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. JCO 28: 2503
-
(2010)
JCO
, vol.28
, pp. 2503
-
-
Infante, J.1
Fecher, L.A.2
Nallapareddy, S.3
Gordon, M.S.4
Flaherty, K.T.5
Cox, D.S.6
Demarini, D.J.7
Morris, S.R.8
Burris, H.A.9
Messersmith, W.A.10
-
16
-
-
0038482050
-
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
-
DOI 10.1074/jbc.M301010200
-
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasomedependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816 (Pubitemid 36799262)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.21
, pp. 18811-18816
-
-
Ley, R.1
Balmanno, K.2
Hadfield, K.3
Weston, C.4
Cook, S.J.5
-
17
-
-
1242272924
-
The MAP kinase pathway is required for entry into mitosis and cell survival
-
DOI 10.1038/sj.onc.1207188
-
Liu X, Yan S, Zhou T, Terada Y, Erikson RL (2004) The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23: 763-776 (Pubitemid 38241277)
-
(2004)
Oncogene
, vol.23
, Issue.3
, pp. 763-776
-
-
Liu, X.1
Yan, S.2
Zhou, T.3
Terada, Y.4
Erikson, R.L.5
-
18
-
-
23944439944
-
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
-
DOI 10.1200/JCO.2005.14.415
-
Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281-5293 (Pubitemid 46206982)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.23
, pp. 5281-5293
-
-
LoRusso, P.M.1
Adjei, A.A.2
Varterasian, M.3
Gadgeel, S.4
Reid, J.5
Mitchell, D.Y.6
Hanson, L.7
DeLuca, P.8
Bruzek, L.9
Piens, J.10
Asbury, P.11
Van Becelaere, K.12
Herrera, R.13
Sebolt-Leopold, J.14
Meyer, M.B.15
-
19
-
-
0242521470
-
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function
-
Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, Auberger P (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793 (Pubitemid 37372218)
-
(2003)
Oncogene
, vol.22
, Issue.REV. ISS. 4
, pp. 6785-6793
-
-
Luciano, F.1
Jacquel, A.2
Colosetti, P.3
Herrant, M.4
Cagnol, S.5
Pages, G.6
Auberger, P.7
-
20
-
-
0035992286
-
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition
-
MacKeigan JP, Taxman DJ, Hunter D, Earp 3rd HS, Graves LM, Ting JP (2002) Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8: 2091-2099 (Pubitemid 34753578)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.7
, pp. 2091-2099
-
-
MacKeigan, J.P.1
Taxman, D.J.2
Hunter, D.3
Earp III, H.S.4
Graves, L.M.5
Ting, J.P.-Y.6
-
21
-
-
0034920013
-
Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines
-
McDaid HM, Horwitz SB (2001) Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 60: 290-301 (Pubitemid 32678294)
-
(2001)
Molecular Pharmacology
, vol.60
, Issue.2
, pp. 290-301
-
-
McDaid, H.M.1
Horwitz, S.B.2
-
22
-
-
16844386676
-
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants
-
DOI 10.1158/0008-5472.CAN-04-4391
-
McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Perez-Soler R, Horwitz SB (2005) Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 65: 2854-2860 (Pubitemid 40490089)
-
(2005)
Cancer Research
, vol.65
, Issue.7
, pp. 2854-2860
-
-
McDaid, H.M.1
Lopez-Barcons, L.2
Grossman, A.3
Lia, M.4
Keller, S.5
Perez-Soler, R.6
Horwitz, S.B.7
-
23
-
-
81055147625
-
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2
-
Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S (2011) Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 118: 5189-5200
-
(2011)
Blood
, vol.118
, pp. 5189-5200
-
-
Pei, X.Y.1
Dai, Y.2
Youssefian, L.E.3
Chen, S.4
Bodie, W.W.5
Takabatake, Y.6
Felthousen, J.7
Almenara, J.A.8
Kramer, L.B.9
Dent, P.10
Grant, S.11
-
24
-
-
14844285975
-
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
-
DOI 10.1200/JCO.2004.01.185
-
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462 (Pubitemid 41185111)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.22
, pp. 4456-4462
-
-
Rinehart, J.1
Adjei, A.A.2
LoRusso, P.M.3
Waterhouse, D.4
Hecht, J.R.5
Natale, R.B.6
Hamid, O.7
Varterasian, M.8
Asbury, P.9
Kaldjian, E.P.10
Gulyas, S.11
Mitchell, D.Y.12
Herrera, R.13
Sebolt-Leopold, J.S.14
Meyer, M.B.15
-
25
-
-
0032747134
-
Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase
-
Scheid MP, Schubert KM, Duronio V (1999) Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 274: 31108-31113
-
(1999)
J Biol Chem
, vol.274
, pp. 31108-31113
-
-
Scheid, M.P.1
Schubert, K.M.2
Duronio, V.3
-
26
-
-
10344258041
-
Targeting the mitogen-activated protein kinase cascade to treat cancer
-
DOI 10.1038/nrc1503
-
Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947 (Pubitemid 39626217)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.12
, pp. 937-947
-
-
Sebolt-Leopold, J.S.1
Herrera, R.2
-
27
-
-
26644449670
-
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
-
DOI 10.1016/j.ccr.2005.09.006, PII S1535610805002990
-
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297 (Pubitemid 41443414)
-
(2005)
Cancer Cell
, vol.8
, Issue.4
, pp. 287-297
-
-
She, Q.-B.1
Solit, D.B.2
Ye, Q.3
O'Reilly, K.E.4
Lobo, J.5
Rosen, N.6
-
28
-
-
17644421083
-
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
-
DOI 10.1016/j.ccr.2005.02.008
-
Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E (2005) Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7: 227-238 (Pubitemid 40568682)
-
(2005)
Cancer Cell
, vol.7
, Issue.3
, pp. 227-238
-
-
Tan, T.-T.1
Degenhardt, K.2
Nelson, D.A.3
Beaudoin, B.4
Nieves-Neira, W.5
Bouillet, P.6
Villunger, A.7
Adams, J.M.8
White, E.9
-
29
-
-
34250739960
-
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
-
DOI 10.1158/1078-0432.CCR-06-2979
-
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: 3682-3688 (Pubitemid 46955132)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.12
, pp. 3682-3688
-
-
Wilkinson, R.W.1
Odedra, R.2
Heaton, S.P.3
Wedge, S.R.4
Keen, N.J.5
Crafter, C.6
Foster, J.R.7
Brady, M.C.8
Bigley, A.9
Brown, E.10
Byth, K.F.11
Barrass, N.C.12
Mundt, K.E.13
Foote, K.M.14
Heron, N.M.15
Jung, F.H.16
Mortlock, A.A.17
Boyle, F.T.18
Green, S.19
-
30
-
-
0033613250
-
2/M transition of the cell cycle in mammalian fibroblasts
-
DOI 10.1073/pnas.96.20.11335
-
Wright JH, Munar E, Jameson DR, Andreassen PR, Margolis RL, Seger R, Krebs EG (1999) Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci USA 96: 11335-11340 (Pubitemid 29487381)
-
(1999)
Proceedings of the National Academy of Sciences of the United States of America
, vol.96
, Issue.20
, pp. 11335-11340
-
-
Wright, J.H.1
Munar, E.2
Jameson, D.R.3
Andreassen, P.R.4
Margolis, R.L.5
Seger, R.6
Krebs, E.G.7
-
31
-
-
4444251799
-
Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro
-
Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P (2003) Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2: 670-676
-
(2003)
Cancer Biol Ther
, vol.2
, pp. 670-676
-
-
Yacoub, A.1
Han, S.I.2
Caron, R.3
Gilfor, D.4
Mooberry, S.5
Grant, S.6
Dent, P.7
-
32
-
-
34447537796
-
Irradiation-induced G2/M checkpoint response requires ERK1/2 activation
-
DOI 10.1038/sj.onc.1210268, PII 1210268
-
Yan Y, Black CP, Cowan KH (2007) Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26: 4689-4698 (Pubitemid 47067411)
-
(2007)
Oncogene
, vol.26
, Issue.32
, pp. 4689-4698
-
-
Yan, Y.1
Black, C.P.2
Cowan, K.H.3
-
33
-
-
0034948613
-
Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway
-
Yu C, Wang S, Dent P, Grant S (2001) Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 60: 143-154 (Pubitemid 32595242)
-
(2001)
Molecular Pharmacology
, vol.60
, Issue.1
, pp. 143-154
-
-
Yu, C.1
Wang, S.2
Dent, P.3
Grant, S.4
-
34
-
-
33750611606
-
Mps1 Phosphorylation by MAP Kinase Is Required for Kinetochore Localization of Spindle-Checkpoint Proteins
-
DOI 10.1016/j.cub.2006.07.058, PII S0960982206019634
-
Zhao Y, Chen RH (2006) Mps1 phosphorylation by MAP kinase is required for kinetochore localization of spindle-checkpoint proteins. Curr Biol 16: 1764-1769 (Pubitemid 44691789)
-
(2006)
Current Biology
, vol.16
, Issue.17
, pp. 1764-1769
-
-
Zhao, Y.1
Chen, R.-H.2
|